drugset
drugset / Trial / NCT06078566

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201

NCT06078566 ↗

Phase 1/2 Terminated 1 enrolled Auregen Biotherapeutics, SA
NaSingle-groupOpen-labelTreatment

Summary

Long-term follow-up of unilateral microtia patients implanted with AUR-201.

Timeline

Start
2024-01-26
Primary completion
2025-11-14
Completion
2025-11-14

Outcome

Outcome not reported

Stopped (Business): “Business reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject AUR-201 Cell therapy — Subcutaneous

Indications

microtia